Ipsen gets in on ADC action with Sutro deal
引进/卖出抗体药物偶联物上市批准临床1期
French drugmaker Ipsen has inked a global licensing agreement with Sutro Biopharma for an antibody-drug conjugate in the final stages of preclinical development.
Ipsen’s will pick up its first ADC candidate through the deal. The asset, STRO-003, targets the ROR1 tumor antigen known to be overexpressed in many different cancer types including solid tumors and hematological malignancies.
Under the terms of the agreement, Ipsen will hand California-based Sutro up to $900 million in upfront payments including an equity investment and tiered royalties on global sales. Ipsen will take over the phase 1 preparation activities, including submission of the IND application, and all subsequent clinical development and global commercialization.
Ipsen just had a big oncology win back in February when the FDA approved the drugmaker's liposomal topoisomerase inhibitor, Onivyde, in combination with oxaliplatin, fluorouracil and leucovorin as a first-line treatment for metastatic pancreatic adenocarcinoma, a particularly aggressive form of cancer with limited treatment options and a poor prognosis.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。